Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-09-24
DOI
10.3389/fimmu.2020.549842
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
- (2019) John F. Foley et al. Multiple Sclerosis and Related Disorders
- A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients
- (2019) Antonino Cassotta et al. NATURE MEDICINE
- Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
- (2019) Jan W. Traub et al. Journal of Neuroinflammation
- T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention
- (2018) Jamie van Langelaar et al. BRAIN
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- (2018) Raju Kapoor et al. LANCET NEUROLOGY
- Multiple Sclerosis: Mechanisms and Immunotherapy
- (2018) Clare Baecher-Allan et al. NEURON
- Efficacy and safety of natalizumab extended interval dosing
- (2018) Bassem I. Yamout et al. Multiple Sclerosis and Related Disorders
- Therapeutic drug monitoring of natalizumab
- (2018) Masami Tanaka Multiple Sclerosis Journal
- Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
- (2018) Maxi Kaufmann et al. Frontiers in Neurology
- John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients
- (2017) Z. L. E. van Kempen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Recognition of viral and self-antigens by T H 1 and T H 1/T H 17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses
- (2017) Moira Paroni et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis
- (2017) Sonia Villani et al. JOURNAL OF NEUROIMMUNOLOGY
- The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
- (2017) Zoé LE van Kempen et al. Multiple Sclerosis Journal
- Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
- (2017) Tatiana Plavina et al. NEUROLOGY
- The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
- (2017) Zoé LE van Kempen et al. Multiple Sclerosis Journal
- Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
- (2017) Inés González-Suarez et al. Brain and Behavior
- Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis
- (2016) Álvaro Cobo-Calvo et al. CLINICAL IMMUNOLOGY
- New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies
- (2016) T. Sehr et al. Journal of Neuroinflammation
- Extended interval dosing of natalizumab in multiple sclerosis
- (2016) L Zhovtis Ryerson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Reassessing the risk of natalizumab-associated PML
- (2016) Joseph R. Berger et al. JOURNAL OF NEUROVIROLOGY
- Persistence and pathogenesis of the neurotropic polyomavirus JC
- (2015) Hassen S. Wollebo et al. ANNALS OF NEUROLOGY
- High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis
- (2015) A. Harrer et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab
- (2015) Simone Dallari et al. JOURNAL OF NEUROIMMUNOLOGY
- Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis
- (2015) E Signoriello et al. Multiple Sclerosis Journal
- Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis
- (2015) M. Mattoscio et al. NEUROLOGY
- Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis
- (2015) E Signoriello et al. Multiple Sclerosis Journal
- JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis
- (2014) Spyridon Chalkias et al. ANNALS OF NEUROLOGY
- Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab
- (2014) T. Koudriavtseva et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells
- (2014) Tilman Schneider-Hohendorf et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lymphocyte Gene Expression and JC Virus Noncoding Control Region Sequences Are Linked with the Risk of Progressive Multifocal Leukoencephalopathy
- (2014) L. J. Marshall et al. JOURNAL OF VIROLOGY
- Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study
- (2014) R Mancuso et al. Multiple Sclerosis Journal
- Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF
- (2014) Clemens Warnke et al. Multiple Sclerosis Journal
- MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
- (2014) R. J. Fox et al. NEUROLOGY
- JC Virus in CD34+and CD19+Cells in Patients With Multiple Sclerosis Treated With Natalizumab
- (2014) Elliot M. Frohman et al. JAMA Neurology
- Extended interval dosing of natalizumab: a two-center, 7-year experience
- (2014) Roberto Bomprezzi et al. Therapeutic Advances in Neurological Disorders
- Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
- (2013) P. Wipfler et al. ACTA NEUROLOGICA SCANDINAVICA
- Increased B Cell and Cytotoxic NK Cell Proportions and Increased T Cell Responsiveness in Blood of Natalizumab-Treated Multiple Sclerosis Patients
- (2013) Johan Mellergård et al. PLoS One
- Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis
- (2012) Luisa M. Villar ARCHIVES OF NEUROLOGY
- TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
- (2012) Celia Oreja-Guevara et al. BMC Neurology
- Prediction of antibody persistency from antibody titres to natalizumab
- (2012) Poul Erik H Jensen et al. Multiple Sclerosis Journal
- Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy
- (2012) A Harrer et al. Multiple Sclerosis Journal
- Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
- (2012) Anke Vennegoor et al. Multiple Sclerosis Journal
- Characterization of anti-natalizumab antibodies in multiple sclerosis patients
- (2012) M Lundkvist et al. Multiple Sclerosis Journal
- Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis
- (2012) Andrea Harrer et al. PLoS One
- Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis
- (2012) Clara de Andrés et al. PLoS One
- Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis
- (2012) Lars Börnsen et al. PLoS One
- Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody
- (2011) Theo Rispens et al. ANALYTICAL BIOCHEMISTRY
- Natalizumab and Impedance of the Homing of CD34+ Hematopoietic Progenitors
- (2011) Christian Saure ARCHIVES OF NEUROLOGY
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
- (2011) Cris S Constantinescu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis
- (2011) Raquel Planas et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
- (2011) Jaime Ramos-Cejudo et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE
- (2011) Veit Rothhammer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: Loss of 4 Integrin Expression Differentially Affects the Homing of Th1 and Th17 Cells
- (2011) S. Glatigny et al. JOURNAL OF IMMUNOLOGY
- Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells
- (2011) Andrea Harrer et al. JOURNAL OF NEUROIMMUNOLOGY
- CD49d expression as a promising biomarker to monitor natalizumab efficacy
- (2011) Gilles Defer et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation
- (2011) Laura Codarri et al. NATURE IMMUNOLOGY
- The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF
- (2011) Mohamed El-Behi et al. NATURE IMMUNOLOGY
- Assessment of JC virus DNA in blood and urine from natalizumab-treated patients
- (2010) Richard A. Rudick et al. ANNALS OF NEUROLOGY
- CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function
- (2010) D Jing et al. BONE MARROW TRANSPLANTATION
- Human Polyomavirus JC (JCV) Infection of Human B Lymphocytes: A Possible Mechanism for JCV Transmigration across the Blood‐Brain Barrier
- (2010) Moti L. Chapagain et al. JOURNAL OF INFECTIOUS DISEASES
- Natalizumab has no direct biological effect on JC virus infectivity in permissive human neural cell lines
- (2010) Tadaki Suzuki et al. JOURNAL OF MEDICAL VIROLOGY
- CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus
- (2010) Clemens Warnke et al. Multiple Sclerosis Journal
- CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment
- (2010) Giovanni Frisullo et al. Multiple Sclerosis Journal
- Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
- (2009) Kenneth R Carson et al. LANCET ONCOLOGY
- Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
- (2009) Aran F Labrijn et al. NATURE BIOTECHNOLOGY
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
- (2009) B. O. Khatri et al. NEUROLOGY
- Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
- (2009) Yiping Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of JC virus DNA fragments but not proteins in normal brain tissue
- (2008) Georgina Perez-Liz et al. ANNALS OF NEUROLOGY
- Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
- (2008) Maria del Pilar Martin ARCHIVES OF NEUROLOGY
- The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
- (2008) F. Zohren et al. BLOOD
- Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
- (2008) H. Bonig et al. BLOOD
- Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy
- (2008) Angela Marzocchetti et al. JOURNAL OF NEUROVIROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
- (2008) Max-Philipp Stenner et al. PLoS One
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started